Dilip Ceramics dba Shivam Distributors lacked Foreign Supplier Verification Program (FSVP) coverage for imported cumin, red lentils, basmati rice.
What happened
FDA conducted an FSVP inspection of records the company submitted electronically from December 29, 2020 through January 6, 2021. FDA found no FSVP for cumin powder and found the company had not done required hazard analysis, supplier evaluation and approval, or verification activities for red lentils and basmati rice. The investigator provided a Form FDA 483a at the close, and FDA said it received no response.
What FDA found
The company did not develop, maintain, and follow a Foreign Supplier Verification Program (FSVP) for cumin powder it imports.
section 805 of the FD&C Act; 21 CFR 1.502(a)For red lentils and basmati rice, the company did not prepare a written hazard analysis to identify and evaluate known or reasonably foreseeable hazards.
21 CFR 1.504The company did not evaluate its foreign suppliers’ performance and the risk posed by the foods, and did not document approval of those suppliers.
21 CFR 1.505(a), (b)The company did not establish written procedures for ensuring appropriate supplier verification activities were conducted.
21 CFR 1.506(b)The company did not document its determination of the appropriate supplier verification activity or activities.
21 CFR 1.506(d)For supplier verification, the company did not show it reviewed and assessed the third-party audit or kept required sampling and testing records.
21 CFR 1.506(e)
What FDA wants
Respond in writing within 15 working days from receipt, addressing the violations and including documentation such as a copy of the FSVP and records showing implementation. If all corrections cannot be completed in 15 days, explain the delay and state when remaining violations will be corrected.
Who should pay attention
- U.S. food importers of spices, lentils, and rice
- brands and retailers buying imported cumin, lentils, or basmati rice
- companies relying on foreign supplier audits or certificates
This is a summary. Read the original letter on fda.gov.